G quadruplex ligands to treat infectious diseases

The present inventions relate to - metallated porphyrin derivatives as ligands of G quadruplex and their use as anti-viral agents. Porphyrin derivatives candidates inhibits HIV replication with IC 50 around 100 nM in vitro. More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle; -methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one G4 forming sequence oligonucleotide; - novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV) , Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus (KSHV). In particular, the invention relates to novel compound derivatives that are shown to be G-quadruplex ligands and are thus useful for treating the above infections. Also the invention relates to the process of preparation of the novel compound derivatives.

Keywords: Virology, HIV, G4-Quadruplex, Ebola
Patent Application number: EP15 306 737.6
Inventors:
ANDREOLA Samir AMRANE Jean-Louis MERGNY Geneviève PRATVIEL
Publications:
Biochimie. 2015 Nov;118:173-5. doi: 10.1016/j.biochi.2015.09.009. Epub 2015 Sep 10. Review Nucleic Acids Res. 2014 Nov 10;42(20):12352-66. doi: 10.1093/nar/gku999. Epub 2014 Oct 20. Dalton Trans. 2019 May 7;48(18):6091-6099. doi: 10.1039/c8dt04703k.

Reference:

CHIM14143-T1

Business Developper
contact
Inserm Transfert
Inserm Transfert
Business Developer
Patent filling date: 2015-10-30

You might also be interested in